Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

ABSTRACT: Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

PROVIDER: PRJNA499054 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8128650_1.fastq.gz	Fastqsanger.gz
	SRR8128650_2.fastq.gz	Fastqsanger.gz
	SRR8128660_1.fastq.gz	Fastqsanger.gz
	SRR8128660_2.fastq.gz	Fastqsanger.gz
	SRR8128670_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 224

Similar Datasets

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Project description:Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years. To better understand and identify these ‘high-risk’ cases, we analyzed the translocation landscape of myeloma from 795 newly-diagnosed patients by whole genome sequencing from the CoMMpass study. Translocations involving the immunoglobulin lambda (IgL) locus were identified in 10% of patients, and were indicative of poor prognosis. Importantly, 70% of IgL translocations co-occurred with hyperdiploid disease, a marker of standard risk, potentially resulting in the misclassification of IgL-translocated myeloma. Most IgL-translocations coincided with focal amplifications that were centered on the 3’ enhancer. Patients with IgL-translocations failed to benefit from immunomodulatory imide drugs (IMiDs), which target the lymphocyte-specific transcription factor IKZF1 that is bound to the IgL 3’ enhancer at some of the highest levels in the myeloma epigenome. These data implicate IgL-translocation as a driver of poor prognosis which may be due in part to IMID resistance.

2019-03-13 | GSE121912 | GEO

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Project description:Multiple myeloma is a malignancy of antibody-secreting plasma cells. Most patients benefit from current therapies, however, 20% of patients relapse or die within two years and are deemed high risk. Here we analyze structural variants from 795 newly-diagnosed patients as part of the CoMMpass study. We report translocations involving the immunoglobulin lambda (IgL) locus are present in 10% of patients, and indicative of poor prognosis. This is particularly true for IgL-MYC translocations, which coincide with focal amplifications of enhancers at both loci. Importantly, 78% of IgL-MYC translocations co-occur with hyperdiploid disease, a marker of standard risk, suggesting that IgL-MYC-translocated myeloma is being misclassified. Patients with IgL-translocations fail to benefit from IMiDs, which target IKZF1, a transcription factor that binds the IgL enhancer at some of the highest levels in the myeloma epigenome. These data implicate IgL translocation as a driver of poor prognosis which may be due to IMiD resistance.

| S-EPMC6478743 | biostudies-literature

Distinct gene expression profile between ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis groups

Project description:Cancer tissue specimens from ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis of patients with advanced gastric cancer were extracted and analyzed.

2018-02-06 | GSE110078 | GEO

Distinct gene expression profile between ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis groups

Project description:Distinct gene expression profile between ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis groups

| PRJNA432896 | ENA

MYC regulation of a "poor prognosis" metastatic cancer cell state

Project description:MYC regulation of a "poor prognosis" metastatic cancer cell state

| PRJNA111899 | ENA

Gastric and esophagogastric junction adenocarcinoma with infrequent hypermethylation show poor prognosis

Project description:Gastric and esophagogastric junction adenocarcinoma with infrequent hypermethylation show poor prognosis

| PRJNA857438 | ENA

Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma

Project description:Trps1 predicts poor prognosis in advanced high grade serous ovarian carcinoma